Literature DB >> 16314489

Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.

Yuan Zhu1, Takayuki Harada, Li Liu, Mark E Lush, Frantz Guignard, Chikako Harada, Dennis K Burns, M Livia Bajenaru, David H Gutmann, Luis F Parada.   

Abstract

The gene responsible for neurofibromatosis type 1 (NF1) encodes a tumor suppressor that functions as a negative regulator of the Ras proto-oncogene. Individuals with germline mutations in NF1 are predisposed to the development of benign and malignant tumors of the peripheral and central nervous system (CNS). Children with this disease suffer a high incidence of optic gliomas, a benign but potentially debilitating tumor of the optic nerve; and an increased incidence of malignant astrocytoma, reactive astrogliosis and intellectual deficits. In the present study, we have sought insight into the molecular and cellular basis of NF1-associated CNS pathologies. We show that mice genetically engineered to lack NF1 in CNS exhibit a variety of defects in glial cells. Primary among these is a developmental defect resulting in global reactive astrogliosis in the adult brain and increased proliferation of glial progenitor cells leading to enlarged optic nerves. As a consequence, all of the mutant optic nerves develop hyperplastic lesions, some of which progress to optic pathway gliomas. These data point to hyperproliferative glial progenitors as the source of the optic tumors and provide a genetic model for NF1-associated astrogliosis and optic glioma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314489      PMCID: PMC2760350          DOI: 10.1242/dev.02162

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  50 in total

1.  Modification of glial-neuronal cell interactions prevents photoreceptor apoptosis during light-induced retinal degeneration.

Authors:  T Harada; C Harada; N Nakayama; S Okuyama; K Yoshida; S Kohsaka; H Matsuda; K Wada
Journal:  Neuron       Date:  2000-05       Impact factor: 17.173

2.  Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas.

Authors:  D H Gutmann; J Donahoe; T Brown; C D James; A Perry
Journal:  Neuropathol Appl Neurobiol       Date:  2000-08       Impact factor: 8.090

Review 3.  Mammalian neural stem cells.

Authors:  F H Gage
Journal:  Science       Date:  2000-02-25       Impact factor: 47.728

4.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

Authors:  Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

5.  Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation.

Authors:  D H Gutmann; A Loehr; Y Zhang; J Kim; M Henkemeyer; A Cashen
Journal:  Oncogene       Date:  1999-08-05       Impact factor: 9.867

6.  Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.

Authors:  N Lau; M M Feldkamp; L Roncari; A H Loehr; P Shannon; D H Gutmann; A Guha
Journal:  J Neuropathol Exp Neurol       Date:  2000-09       Impact factor: 3.685

7.  Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo.

Authors:  Melissa M Fraser; Xiaoyan Zhu; Chang-Hyuk Kwon; Erik J Uhlmann; David H Gutmann; Suzanne J Baker
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo.

Authors:  Biplab Dasgupta; David H Gutmann
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.167

Review 9.  Intracranial gliomas in neurofibromatosis type 1.

Authors:  R Listernick; J Charrow; D H Gutmann
Journal:  Am J Med Genet       Date:  1999-03-26

Review 10.  Neurofibromatosis type 1 - a model for nervous system tumour formation?

Authors:  Joshua B Rubin; David H Gutmann
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

View more
  97 in total

Review 1.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

2.  CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.

Authors:  Tao Sun; Scott M Gianino; Erin Jackson; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  J Neuroimmunol       Date:  2010-07-27       Impact factor: 3.478

3.  Evidence for and against regional differences in neural stem and progenitor cells of the CNS.

Authors:  Oren J Becher; Eric C Holland
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

4.  Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Authors:  Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

5.  VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling.

Authors:  Lingchao Chen; Lei Han; Kailiang Zhang; Zhendong Shi; Junxia Zhang; Anling Zhang; Yongzhi Wang; Yijun Song; Yongli Li; Tao Jiang; Peiyu Pu; Chuanlu Jiang; Chunsheng Kang
Journal:  Neuro Oncol       Date:  2012-05-30       Impact factor: 12.300

Review 6.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 7.  Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights.

Authors:  Kimberly Ng; Ryan Kim; Santosh Kesari; Bob Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2011-10-16       Impact factor: 4.130

Review 8.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

9.  ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.

Authors:  Yuan Wang; Edward Kim; Xiaojing Wang; Bennett G Novitch; Kazuaki Yoshikawa; Long-Sheng Chang; Yuan Zhu
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

10.  Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production.

Authors:  Georgette N Jones; Chhavy Tep; William H Towns; Georgeta Mihai; Ian D Tonks; Graham F Kay; Petra M Schmalbrock; Anat O Stemmer-Rachamimov; Sung Ok Yoon; Lawrence S Kirschner
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.